Brazil’s health regulatory agency, ANVISA, has ordered the seizure and recall of a FarmaUSA tirzepatide compounding lot after the company failed to destroy a previously interdicted batch. The action marks one of the first formal enforcement moves by a major regulator specifically targeting tirzepatide compounding products.
In a separate resolution, ANVISA banned the manufacture, import, advertising, and use of unregistered tirzepatide and retatrutida products offered on named Brazilian websites. The agency cited Brazil’s federal drug law (Lei nº 6.360/1976) as well as GLP-1-specific rules (RDC 625/2022 and Despacho nº 97/2025) as legal authority for its actions.
What happened
Under Resolução-RE nº 4.009, ANVISA prohibited the sale, distribution, manipulation, and use of FarmaUSA lot HXTZ251015, a tirzepatide freeze-dried powder intended for compounding. The regulator ordered its seizure and recall after FarmaUSA reportedly failed to destroy a batch that had previously been interdicted.
In a parallel action, Resolução-RE nº 4.035 targeted unregistered tirzepatide and retatrutida products sold online through sites including Peptídeos do Brasil and ZPHC Store. ANVISA ordered their removal and seizure, banning their manufacture, import, advertising, and use within Brazil.
ANVISA did not report confirmed quality failures or patient cases linked specifically to the seized FarmaUSA lot. The agency said it is separately investigating adverse-event reports, including alleged cases of vision loss tied to so-called canetas emagrecedoras (weight-loss pens), but that optic-nerve injury review is an unrelated inquiry and not part of these two enforcement actions.
Why it matters
This is among the first formal enforcement actions by a major regulatory body specifically naming tirzepatide compounding products in connection with an adverse-event investigation. It signals that international regulators are moving beyond guidance documents to active enforcement against noncompliant peptide supply chains.
The actions could affect compounding pharmacies selling GLP-1 products internationally, telehealth platforms serving Brazilian patients, and peptide importers and distributors who source from similar channels. In this case, FarmaUSA’s failure to comply with an earlier interdiction order escalated to a formal seizure and recall.
What to watch next
- Whether ANVISA expands enforcement to additional compounding lots or suppliers of GLP-1 peptides.
- Whether other national regulators follow Brazil’s approach of naming specific websites and product lots in formal resolutions.
- Outcomes of ANVISA’s separate investigation into adverse-event reports, including alleged vision-loss cases linked to weight-loss pens.
- Any impact on U.S.-based compounding pharmacies that export to Brazil or source raw materials from overlapping supply chains.
Sources
- Particle News — ANVISA orders seizure of FarmaUSA tirzepatide lot and bans unregistered online GLP-1 products
- Olhar Digital — ANVISA proíbe venda de canetas de tirzepatida sem registro no Brasil
Industry information only. Not medical or legal advice.
